Business Today US India IPR FDA Pharma Sector
Alchemy by E Kumar Sharma
Fresh salvo in the turf battle between innovator & generic drug makers

Every business has the right to adopt legitimate practises to protect their own interest. Right? But a recent article argues that going beyond the patent act, which permits research and development during the life of a patent, some innovator drug companies are busy trying to block this.

On October 20th the ministry of chemicals and fertilizers issued a press note in what seems an attempt to allay industry fears on the issue of price controls.
High profile investment melas by Indian states, backed by big numbers to showcase potential investor interest, are par-for-the-course today.
Water, as things stand today, is a state subject even though ground water management is a national priority.